Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with Recurrent progression to myelofibrosis. Existing cysteine-depletion oral cysteamine therapy won't reach the avascular corneal tissues so it's ineffective in treating ocular (corneal) cystinosis.22 the pursuit of NACA therapy for treatment of HCCAA is warranted. To even more look into the purpose https://englandt742kpt5.wikijm.com/user